Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is poised for growth with California Senate Bill 729, expansion into new markets, and a focus on customer retention and profitability through efficient use of technology. Despite potential risks, the company remains optimistic and confident in their strong start to the year and expects to continue executing efficiently. With a strong competitive advantage and a target of 1M new members by 2027, Progyny's focus on fertility, family building, and women's health benefits solutions make it well-positioned for success in the expanding market.

Bears say

Progyny is a strong standalone fertility benefits management companies in the US, with a competitive edge due to its deep integration into clinical workflows driving a ~93% attachment rate. However, the lack of diversification in its revenue streams and potential competition from unbundled solutions may pose challenges for future growth. The company's strong focus on clinical outcomes and differentiated provider network provides a favorable positioning, but investors should closely monitor its client retention and competition risks.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.